Printer Friendly

NEORX RECEIVES FDA CLEARANCE FOR AVICIDIN STUDY

 SEATTLE, Dec. 10 /PRNewswire/ -- NeoRx Corporation (NASDAQ-NMS: NERX) today announced that it has received clearance from the Food and Drug Administration to begin a Phase I study of its Avicidin(TM) cancer therapy product. Avicidin employs the Company's patented and proprietary pretargeting technology.
 The purpose of this study is to demonstrate that the Avicidin product performs in humans as would be predicted from earlier studies in animals.
 The Company's Avicidin cancer therapy products under development employ its proprietary pretargeting technology, which results in the localization of antibodies at the tumor sites prior to administration of a radioactive isotope which then binds to the antibody. Pretargeting is designed to allow delivery of high doses of radiation to tumor cells while minimizing toxicity to normal tissue associated with conventional therapy. In preclinical studies in animals, the company's pretargeting technology achieved a significant improvement in the therapeutic ratio (the dose delivered to tumor divided by the dose delivered to blood) compared to conventional radioimmunotherapy accompanied by rapid, complete regressions of chemotherapy-resistant human lung cancer tumors.
 NeoRx is developing Avicidin initially for small cell lung cancer and believes that indications for non-small cell lung cancer, colon cancer and breast cancer may also be developed using the same or similar pretargeting technology.
 NeoRx develops targeted biopharmaceuticals that detect and treat human diseases. To date, the Company's activities have been primarily devoted to developing monoclonal antibody-based pharmaceutical products for the diagnosis and treatment of certain types of cancer, NeoRx's lead product under development is a lung cancer diagnostic imaging product, for which the Company has filed with the FDA a Product License Application. The Company's cancer therapy products under development employ its proprietary pretargeting technology, which is designed to deliver high doses of radiation to tumor cells while minimizing toxicity to normal tissue as compared with conventional chemotherapy and radiation treatment. The Company is also developing a product designed to reduce restenosis following coronary balloon angioplasty.
 -0- 12/10/93
 /CONTACT: Robert M. Littauer, Senior Vice President, Chief Financial Officer of NeoRx, 206-286-2519; or Anthony J. Russo, Ph.D., or Kathryn Comba of Noonan/Russo Communications, 212-696-4455/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU:

WB-SH -- NY070 -- 2724 12/10/93 15:11 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 10, 1993
Words:369
Previous Article:MAGELLAN SETS DATE FOR ANNUAL MEETING
Next Article:PRUDENTIAL HOME MORTGAGE CERTIFICATES 1993-63 RATED 'AAA/AA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters